HIGHLIGHTS
Photochemistry is combined with radiochemistry for radiosynthesis in a flash Simultaneous photoradiochemistry is achieved with high radiolabeling efficiency Photoradiochemistry produces viable 89 Zrradiolabeled antibodies Density functional theory calculations elucidate the photoactivation mechanism
INTRODUCTION
The use of photochemically activated compounds for labeling proteins and other biologically active molecules was introduced by Westheimer and co-workers in 1962 (Singh et al., 1962) . Since then, photoaffinity labeling (PAL) has matured, and a wide array of reagents are available for studying the structure and function of biological systems (Bayley and Knowles, 1977; Chowdhry and Westheimer, 1979; Kotzyba-Hilbert et al., 1995) . Photochemical activation offers a number of advantages over thermochemical processes. For instance, photoreactive groups can be selected whereby, (1) the reagent is stable under ambient conditions, (2) photoactivation occurs specifically at a wavelength that is not absorbed by the biological vector, and (3) the conjugation step involves a chemoselective reaction with the target molecule. Furthermore, because photochemical activation proceeds via an excited electronic state that generates extremely reactive intermediates like carbenes, nitrenes, and radicals, the rates of photochemical conjugation reactions can be several orders of magnitude faster than those of standard methods (Dennler et al., 2015; Gritsan and Platz, 2006; Klá n and Wirz, 2009; Platz, 1995) . High reactivity of the photo-induced intermediates presents both advantages and disadvantages. One of the benefits is that photoactive reagents can yield high labeling efficiencies in short reaction times. However, to achieve efficient conjugation, PAL methods often rely on a mechanism in which the photoactive reagent and the target protein form a non-covalent pre-association complex. Pre-association facilitates pseudo-first-order intramolecular bond formation and minimizes the probability of quenching by background media (i.e., by the solvent, oxygen, salts, etc.). However, the problem with this approach is that it restricts most PAL tools to systems that self-assemble.
From the radiochemistry perspective, photochemical reactions are an attractive platform for developing radiotracers. For molecules that undergo radioactive decay, chemical kinetics is one of the main factors in determining if a reaction is suitable for use in radiotracer synthesis (Holland, 2018) . As photochemical reactions often proceed with rate constants that tend toward the rate of diffusion, combining photochemistry with radiochemistry (photoradiochemistry) is a logical step.
Several groups have reported the use of photochemical reactions in the synthesis of radiolabeled compounds (Hashizume et al., 1995; Kumar et al., 2015; Kym et al., 1995; Lange et al., 2002; Nishikawa et al., 2003; Pandurangi et al., 1997a Pandurangi et al., , 1997c 1997b , 1998 Rajagopalan et al., 2002; Stalteri and Mather, 1996; Sykes et al., 1995 Sykes et al., , 1997 Wester et al., 1996) . However, it is surprising that to date, photochemistry has had minimal impact on radiopharmaceutical science. The main bottlenecks to a more widespread use of photoradiochemistry for labeling proteins, peptides, and small molecules are (1) avoiding the need to form a pre-associated complex, (2) controlling chemoselectivity in the presence of competing nucleophiles, and (3) ensuring that the rate of productive bimolecular conjugation exceeds that of background quenching reactions. If a photochemical process can be tuned to favor bimolecular coupling, then photoradiochemistry may become a more general tool in radiotracer synthesis.
A specific area for potential applications of photoradiochemistry is the synthesis of radiolabeled monoclonal antibodies (mAbs) or immunoglobulin fragments for use in positron emission tomography (immuno-PET) and radioimmunotherapy (Boros and Holland, 2018) . Zirconium-89 (t 1/2 = 78.41 h) has emerged as the radionuclide of choice for immuno-PET. In almost all available methods for radiolabeling mAbs, the production of 89 Zr-mAbs relies on a two-step procedure (Scheme 1). Initially, the antibody is purified from a source and then functionalized with a suitable metal-ion-binding chelate. For 89 Zr, the chelate of choice is usually a derivative of desferrioxamine B (DFO), but a number of alternative chelates have been reported (Boros and Holland, 2018) . After conjugation, the functionalized mAb is re-purified, characterized, and stored before radiolabeling. Although this two-step approach is highly successful, there are several drawbacks. First, the conjugation chemistry is time consuming and may involve multiple chemical transformations that risk compromising the biological integrity of the mAb. Second, for applications in the clinic, the conjugation chemistry should ideally be performed in accordance with current Good Manufacturing Practice. Third, the conjugated mAb is a new molecular entity, which may be subject to stringent testing, including expensive toxicological test. Finally, storage of the radiolabeling precursor raises concerns over the long-term chemical and biochemical stability.
We postulated that photoradiochemistry could be used to streamline the production of radiolabeled mAbs (and other radiolabeled proteins or peptides) by simplifying the procedure to a one-pot reaction and eliminating the need to isolate or store the functionalized intermediate. Two mechanistically distinct processes can be envisaged for a one-pot procedure: a two-step pre-radiolabeling approach and a one-step pathway in which the radiolabeling and photochemical conjugation reactions occur simultaneously. Here, we present detailed experimental and theoretical data evaluating the photoradiochemical synthesis of 89 Zr-labeled trastuzumab.
RESULTS AND DISCUSSION
Our initial proof-of-concept studies found that the macrocyclic chelate, (2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl) pentanedioic acid (NODAGA), when functionalized with a photoreactive arylazide (ArN 3 ) facilitated a two-step photoradiolabeling of trastuzumab with 68 Ga 3+ ions (Eichenberger et al., 2019; Patra et al., 2019) . Although technically feasible, the combination of short-lived 68 Ga (t 1/2 = 67.71 min) with mAbs ($150 kDa) is not ideal because of the mismatch between the timescales of radioactive decay and radiotracer pharmacokinetics in vivo. In addition, 68 Ga 3+ radiochemistry usually requires acidic media (to avoid hydrolysis of the metal ion), which is suboptimal for photochemical conjugation using the ArN 3 group (Borden et al., 2000; Gritsan and Platz, 2010, 2006; Gritsan and Pritchina, 1992) . Here, we focused our efforts on developing a photoradiochemical process for producing 89 Zr-labeled mAbs. Zirconium-89 radiochemistry normally starts from the zirconium tetraoxalate anion, [ 89 Zr] [Zr(C 2 O 4 ) 4 ] 4-(aq.), and complexation by DFO derivatives can be accomplished over a wide pH range (from approximately pH 5-10, with optimal yields attained by using pH 6-8.5 ) (Holland and Vasdev, 2014; Vosjan et al., 2010) . Thus 89 Zr-radiochemistry is not only ideal for immuno-PET but also facilitates simultaneous photoradiolabeling.
Chemical and Radiochemical Synthesis
The photoactive chelate DFO-ArN 3 (1) was synthesized by using standard chemical transformations (Scheme 2). The compound was isolated in high purity by semi-preparative high-performance liquid chromatography and characterized by ultrahigh-performance liquid chromatography (UHPLC), high-resolution electrospray ionization mass spectrometry (HR-ESI-MS), one-and two-dimensional 1 H and 13 C nuclear magnetic resonance spectroscopies, and electronic absorption spectroscopy (Transparent Methods Figures S2-S8 ).
The non-radioactive complex, + , was prepared by the reaction of compound 1 with ZrCl 4 (aq.), and characterized by HR-ESI-MS and UHPLC ( Figure 1 and Transparent Methods Figures S9 and S10 was prepared as a single radioactive species, the identity of which was confirmed by comparison of retention times with the authenticated non-radioactive sample and by standard co-injection methods ( Figure 1 , blue radiotrace).
Photochemical Kinetics
After confirming that 89 Zr-1 + could be prepared via standard radiolabeling methods, the photochemical activity of compound 1 was tested under irradiation with UV light. Three separate light sources were tested including two variable-intensity light-emitting diodes (LEDs) with peak emission wavelengths at $365 nm and $395 nm and a high-powered Rayonet reactor (Transparent Methods Figure S1 ). The photochemical degradation kinetics of compound 1, induced by using variable light intensities, was monitored by UHPLC ( Figure 2 and Transparent Methods Table S2 ). Experiments confirmed that compound 1 was photoactive. All peaks in the UHPLC associated with photodegraded products were found to be more hydrophilic than the parent compound, which is consistent with the established mechanism of ArN 3 activation in aqueous media (Klá n and Wirz, 2009) . After light absorption, ArN 3 releases N 2 (g) and forms a short-lived arylnitrene species in the singlet ( 1 A 2 ) ground state (Gritsan and Platz, 2006) . This arylnitrene undergoes rapid intramolecular rearrangement to give benzazirine or ketenimine intermediates (Platz, 1995) . When powerful nucleophiles are present, the ketenimine species reacts to form more polar azepine adducts. In the absence of nucleophiles, hydrolysis reactions can form the 3H-azepin-2-ol or the 1,3-dihydro-2H-azepin-2-one tautomers (Bou-Hamdan et al., 2011). Photo-irradiated samples of compound 1 showed that at least six new species formed ( Figure 2A ). This observation is consistent with the mechanism of activation. The DFO ligand contains several nucleophilic groups (hydroxamates) that can induce intramolecular reactions with the ketenimine intermediate forming various cycles.
By integrating the peak in the UHPLC associated with compound 1, it was possible to measure the photochemical degradation kinetics ( Figure 2B ). At room temperature, and using the LED (365 nm) at different intensities (25%, 50%, and 100%), the photochemical degradation of compound 1 fitted a first-order kinetic scheme (non-linear regression coefficient, R 2 >0.999 at each light intensity). Changes in the observed rate constant, k obs /min À1 , were found to be linearly dependent on the light intensity ( Figure 2C ). These data are consistent with the anticipated photochemical response of molecules containing ArN 3 groups (Gritsan and Platz, 2006; Gritsan and Pritchina, 1992; Klá n and Wirz, 2009 ).
Quantum Yield of Photochemical Activation
How efficient is photochemical activation of the ArN 3 in compound 1? This question can be answered by determining the photochemical quantum yield (F), which is defined as the ratio of the number of reactions (n r ) to the number of photons absorbed (n abs , Equation 
An expression for the number of reactions at time t is given by the change in concentration (c) of the starting material multiplied by the volume (V, Equation 2).
The molar photon flux q 0 m;g is defined as the number of photons in moles (i.e., in units of Einstein) incident on a sample per unit time and can be expressed as the light power (P The fraction of photons absorbed can be expressed as 1 minus the transmittance (T), which can be substituted for the measured absorbance using the Beer-Lambert law (Equation 4).
TðtÞ = 10
ÀAðtÞ ; where AðtÞ = 3 l cðtÞ d
(Equation 4)
The differential photon absorption (dn g ðtÞ) at a given time and wavelength (l) can be calculated by Equation 5 .
Finally, it follows that the quantum yield is given by Equation 6 .
Using experimental values from the kinetics of photochemical degradation of compound 1, a photochemical quantum yield of 4.35% G 0.43% was calculated. This means that around one in every $23 photons that is absorbed (at $365 nm) leads to photochemical activation via loss of N 2 as opposed to relaxation through other radiative or non-radiative (chemical quenching) pathways. These data indicated that photochemical activation of compound 1, and other molecules functionalized with the ArN 3 group, is a highly efficient process.
Density Functional Theory Calculations
Next, to understand the thermochemical stability and photochemical reactivity of compound 1 in more detail, density functional theory (DFT) calculations were performed. The acyclic nature of compound 1 means that the compound has a large degree of conformational freedom. Therefore, to simplify calculation of the reaction coordinate and the electronic excitation profile, the non-substituted arylazide (benzylazide) was used as a model compound. All calculations used the uB3LYP/6-311++G(d,p) level of theory and included a polarizable continuum model (PCM, water). The calculated reaction coordinate is shown in (C) Plot of the normalized observed rate constant versus the normalized LED intensity confirming that photodegradation is first order (gradient $1.0) with respect to light intensity. Figure 3 . Relative changes in the reaction free energy, DG; enthalpy, DH; and entropy DS of each species, including all transition states between the arylazide starting material and the most stable geometric isomer formed (cis-N-methyl-3H-azepin-2-amine) after addition of methylamine to the ketenimine intermediate, are shown. In addition, relative energies of the possible electronic states of the arylnitrene were calculated.
The first feature to note is that formation of transition state 1 (TS1), which corresponds to loss of N 2 from arylazide, has a calculated free energy barrier of 143 kJ mol À1 in solution phase. urations centered on the N atom) are calculated to be higher in energy, with a low probability of populating these states at ambient temperature. The TS2 corresponding to the intramolecular rearrangement of arylnitrene has a calculated barrier of only DDG TS2 = 54 kJ mol À1 , which includes destabilization from the loss of aromaticity. After ring insertion occurs, the benzazirine species (DG = 22 kJ mol À1 ) isomerizes to give the more stable ketenimine intermediate (DG = À3 kJ mol À1 ) via a relatively low-energy TS3 (DG = 37 kJ mol À1 ).
Nucleophilic attack by methylamine (CH 3 NH 2 ) at the 2-position of the ketenimine intermediate proceeds via TS4 (DG = 51 kJ mol À1 ) and initially produces the NH-azepin adduct. This NH-azepin then isomerizes to yield the cis-azepin-2-amine product. Formation of the azepin-2-amine from benzylazide and methylamine is calculated to be thermodynamically spontaneous with an overall reaction free energy of DG = À166 kJ mol À1 . As expected, the main driving force for the initial photoactivation is entropic (N 2 (g)
However, nucleophilic addition to the ketenimine, and similarly, conjugation of a photoactive chelate to a biologically active molecule, is driven primarily by changes in enthalpy (DH = À173 kJ mol À1 ). TD-DFT calculations were used to probe the electronic nature of the photoactivation of arylazide. An overlay of the experimentally measured electronic absorption spectrum of compound 1 (in MeOH) and the TD-DFT-calculated spectrum is presented in Figure 4 (see also Transparent Methods Figure S8 and Table S1 ). Perhaps surprisingly, compound 1, and indeed arylazide compounds like 4-azidobenzoic acid show almost no absorbance at wavelengths above $325 nm. Measurements of the molar absorption coefficients at 365 and 395 nm gave values of 16.9 G 1.9 M À1 cm À1 and 5.2 G 1.3 M À1 cm À1 , respectively. Nevertheless, TD-DFT calculations of the 16 lowest energy excited states (including both singlets and triplets) of arylazide confirmed that excitation bands are present in the wavelength range used to promote the photochemistry. Electronic transitions to six major singlet excited states (assigned as bands A to F) contribute to the measured absorption profile of compound 1 in the region 200-600 nm. Note that at shorter wavelengths, the fit between the calculated and the experimental spectrum is less accurate because of the use of the model arylazide and the continuum solvation model, which do not account for the full electronic complexity or solvation dynamics of compound 1. However, experimental features associated with absorption at wavelengths >250 nm are well reproduced.
TD-DFT calculations allow deconvolution of the change in the electronic density associated with the formation of a particular excited state in terms of electronic mixing between the ground-state molecular orbitals (MOs) ( Figure 5 , and Transparent Methods Table S1 ). MO analysis from TD-DFT calculations performed on benzylazide found that absorption band A (corresponding to excitation to the lowest energy excited singlet state) involves 96.4% mixing of the electron density from the highest occupied MO to the lowest unoccupied molecular orbital (LUMO). Inspection of the MO isosurfaces showed that this transition involves primarily transfer of electron density from a populated pp* orbital of the benzyl ring to the unoccupied, in-plane antibonding pp* orbital centered on the azide group. Populating this excited state weakens the azide bond and stimulates N 2 dissociation. Interestingly, our experimental observations indicate that any wavelength that populates the first excited singlet state can induce arylazide activation. However, test experiments using a shorter-wavelength LED ($275 nm), which populates the second or third excited singlet states (bands B and C, respectively), found negligible photochemical activation of the ArN 3 group (data not shown). This observation is consistent with the TD-DFT calculations, which indicate that bands B and C involve electronic transitions to higher-energy virtual orbitals (LUMO+1 and above). Kasha's rule suggests that relaxation of second and third excited singlet states of ArN 3 should populate the LUMO, but inspection of the MOs shows that this process is symmetry forbidden ( Figure 5 ).
Two-
Step Photochemical Conjugation and 89 
Zr-Radiolabeling of Trastuzumab
Before investigating a simultaneous one-pot photoradiochemical process, experiments were performed using the traditional two-step approach. This route involved the photochemical conjugation between compound 1 and trastuzumab, followed by 89 Zr-radiolabeling (Scheme 3, bottom pathway). The photochemical . Note that the calculated spectrum was produced by using Lorentzian broadening, 20-nm full-width at half maximum. Calculated energies and oscillator strengths (f/a.u.) of the bands corresponding to transitions to the first six excited singlet states with non-zero expectation values are shown by vertical red lines (band details inset). For reference, band energies to the excited triplet states are shown by vertical green lines. The simulated spectrum and all calculated energies are x-shifted by +12 nm for clarity. Molecular orbital contributions involved in the excitation to the main singlet bands are presented in Table S1 .
conjugation was performed at room temperature for 25 min using a Rayonet reactor. The DFO-azepin-trastuzumab conjugate was purified by using a combination of size exclusion chromatography (SEC) methods including spin column centrifugation and preparative PD-10 gel filtration. DFO-azepin-trastuzumab was then radiolabeled with 89 Zr using standard conditions (Holland et al., 2010b (Holland et al., , 2010a Rylova et al., 2016; Verel et al., 2003a Verel et al., , 2003b Vosjan et al., 2010) . Aliquots of the crude radiolabeling mixture were retained, and then the product was purified and formulated in sterile PBS by using standard SEC methods. Analytical measurements on the crude and purified samples of [ 89 Zr] ZrDFO-azepin-trastuzumab were performed using radioactive instant thin-layer chromatography (radio-iTLC), analytical PD-10-SEC, and radioactive SEC-UHPLC ( Figure 6 ).
Experiments confirmed that the DFO-azepin-trastuzumab was radiolabeled efficiently with 89 Zr giving a crude radiochemical conversion (RCC) of >98% after incubating the mixture at room temperature for 15 min. On scaling up the radiolabeling reaction for use in cellular and animal experiments, the final radiochemical yield (RCY) of the purified sample was >99%, and the radiochemical purity (RCP) was measured at >99.5% by analytical PD-10-SEC and >98% by SEC-UHPLC. For the preparations used in the animal studies, the final activity concentration was 29.7 MBq mL À1 , with a decay-corrected molar activity (A m ) of 13.7 MBq nmol À1 of protein for the stock sample used in the normal doses (vide infra).
Further 89 Zr-radiolabeling experiments were performed to measure the radiolabeling kinetics and overall RCC yields of DFO-azepin-trastuzumab samples that were prepared using different initial chelate-to-mAb ratios in the photochemical conjugation step ( Figure 7 and Transparent Methods Figure S11 ). For each sample, the radiolabeling kinetics was monitored by radio-iTLC ( Figure 7A ) and the RCC (%) versus time was plotted ( Figure 7B ). These experiments showed a linear relation between the initial chelate-to-mAb ratio and the overall RCC at equilibrium (time points >60 min, Figure S11 ). Using these data, combined with the experimentally determined molar activity of the stock solution of [ 89 (1) and trastuzumab was estimated to be 3.5% G 0.4% (n = 3). Hence, for the samples used in the biological Note that the isosurfaces were generated by using a contour value of 0.035 and correspond to 96.5% of the total electron density.
studies, an initial chelate-to-mAb ratio of 26.4:1 yielded $0.85 accessible chelates per mAb in the final product.
The radiochemical stability of [ 89 Zr]ZrDFO-azepin-trastuzumab with respect to change in the RCP during incubation in human serum at 37 C for up to 92 h was determined by SEC-UHPLC ( Figure 7C ). Experiments confirmed that the 89 Zr activity remained bound to the mAb (<2% decrease in RCP after 92 h) with essentially no transchelation serum proteins (transferrin, albumin, etc.).
Cellular Saturation Binding Assays (Immunoreactivity)
The biochemical viability of [ 89 Zr]ZrDFO-azepin-trastuzumab was measured by using standard cellular saturation binding assays in accordance with the methods introduced by Lindmo et al.(Junghans, 1999 ; Konishi , 2004; Lindmo et al., 1984) . The human ovarian cancer cell line SK-OV-3 shows high expression of the human epidermal growth factor receptor 2 (HER2/neu), which is the target protein of trastuzumab. Saturation binding experiments confirmed that the protein remained biochemically active with an estimated immunoreactivity fraction between 63% and 74% (n = 2, Figure 8 ). Note that these cellular assays were incubated for only 1 h and the slightly low value of the immunoreactivity is primarily associated with slow binding kinetics. Nevertheless, the immunoreactive fraction is comparable to the reported value of 87% G 7% obtained with [ 89 Zr]ZrDFO-Nsucc-trastuzumab that was conjugated using one of the standard thermochemical routes (N-succinyl activated ester) (Holland et al., 2010a) .
Small-Animal PET Imaging and Biodistribution Studies
After confirming that [ 89 Zr]ZrDFO-azepin-trastuzumab was chemically stable and biochemically active in vitro, the pharmacokinetics and target specificity were evaluated in athymic nude mice bearing subcutaneous SK-OV-3 tumors. PET images were recorded at multiple time points between 2 and 94 h postadministration. Two groups of mice were used. The normal group (n = 5) received a high molar activity formulation (13.7 MBq nmol À1 ), and the blocking group received the same amount of radioactivity but a reduced molar activity of 0.14 MBq nmol À1 . Representative PET images showing coronal and axial planes taken through the center of the tumors are presented in Figure 9 (see also Transparent Methods Figures S12 and S13). PET imaging data were also quantified by drawing volumes-of-interest over various tissues and plotting the data as time-activity bar charts ( Figure 10 , based on quantification of the images in units of percentage injected dose per gram (%ID g À1 ), and Figure S14 for equivalent data using image quantification in units of the mean standardized uptake value). The pharmacokinetic profile and tumor uptake of [ 89 Zr]ZrDFO-azepin-trastuzumab was consistent with previously reported experiments using 89 Zr-DFOradiolabeled trastuzumab produced via traditional coupling chemistries (Holland et al., 2010a) . The effective half-life (t 1/2 (eff)/h) of [ 89 Zr]ZrDFO-azepin-trastuzumab was measured in mice by using a calibrated dosimeter (Transparent Methods Figure S15 ). A value of t 1/2 (eff) = 45.7 G 7.7 h was measured (n = 11; R 2 $ 0.99) with an estimated biological half-life, t 1/2 (biol.) = 109.5 G 18.4 h. No difference was observed between the normal and blocking groups. These data are consistent with previous reports on 89 Zr-radiolabeled trastuzumab (Dijkers et al., 2009; Holland et al., 2010a) .
After the final imaging time point, animals were euthanized and a biodistribution analysis was performed to obtain accurate quantification of the accumulation of 89 Zr in different tissues ( Figure 11 , Table 1 and Transparent Methods Figures S16-S19). Comparison of the biodistribution data between the normal and blocking groups showed a specific accumulation of radioactivity in the tumor (65.8% G 14.2 %ID g À1 in the normal group versus 12.1% G 4.1%ID g À1 in the blocking group, p value = 0.0006). With the exception of the activity retained in the blood pool (7.4% G 1.0 %ID g À1 for the normal versus 4.8% G 1.2 %ID g
À1
for the blocking group [p value = 0.003]), no statistically significant differences were observed between radioactivity accumulation in the background tissues of the two groups of mice. Furthermore, a comparison of the tumor-to-tissue contrast ratios recorded from the biodistribution studies performed on the photoradiochemical product [ 89 Zr]ZrDFO-azepin-trastuzumab and on [ 89 Zr]ZrDFO-Nsucc-trastuzumab produced by a conventional conjugation route showed no statistically significant differences between the two radiotracers (Transparent Methods Figure S20 ). (Holland et al., 2010a) Collectively, the data from experiments performed in vitro, in vivo, and ex vivo indicate that the photoradiochemical route to 89 Zr-radiolabeled trastuzumab yields a radiolabeled compound that is of equivalent quality to other 89 Zr-mAbs produced via established methods.
Simultaneous Photoradiolabeling of Trastuzumab
Previously, we demonstrated that the photoradiochemical approach was successful when radiolabeling either pre-purified mAbs or fully formulated samples (Herceptin) (Patra et al., 2019) . In addition to fast reaction and processing times, a one-pot procedure has the unique advantage of avoiding the need to isolate and characterize the conjugated intermediate antibodies. , compound 1, and trastuzumab (at an initial chelate-tomAb ratio of $29:1) were mixed in water and the pH adjusted to $8-9. Control reactions were performed in the absence of either the chelate (1) or the mAb. Mixtures were stirred gently at room temperature and irradiated using the LED source (365 or 395 nm) for 10 min. Note that in this case stirring appeared to be more important than in our previous experiments with 68 Ga (Patra et al., 2019). After irradiation, the reactions were quenched by the addition of diethylenetriamine pentaacetic acid (DTPA). Aliquots of the crude samples were retained, and a fraction was purified by SEC methods. Crude and purified samples were then analyzed by using radio-iTLC, analytical PD-10-SEC, and SEC-UHPLC methods ( Figure 12 and Transparent Methods Table S3 ).
Analysis of the crude reaction mixtures also indicated that $72%-73% (n = 2, by analytical PD-10-SEC) and $67%-88% (n = 2, by SEC-UHPLC) of the 89 Zr-radioactivity was associated with trastuzumab. Control reactions confirmed that the 89 Zr radioactivity bound to trastuzumab specifically (Figures 12A and 12B, green and yellow traces). After purification, simultaneous photoradiolabeling gave [ 89 Zr]ZrDFO-azepin-trastuzumab with a decay-corrected RCY of $76%, a RCP $97% (measured by SEC-UHPLC), and a molar activity of 0.41 MBq nmol À1 of protein (n = 2). Interestingly, both the 365-and 395-nm LED sources gave equivalent radiochemical conversions. Reactions were complete in <10 min, and the entire process, from non-labeled trastuzumab to formulated [ 89 Zr]ZrDFO-azepin-trastuzumab, was accomplished in <15 min. With a higher intensity light source, it is conceivable that the photoradiochemical synthesis could be accomplished in a few seconds, which would mean that radiotracer production times are limited only by the time required for purification and quality control.
Comparison of the final RCYs measured between the two-step process and the simultaneous (one-step) process indicate that the photochemical conjugation efficiency increased from 3.5% to $76%. This result 001. An equivalent plot using units of standardized uptake value is presented in Figure S17 . Data showing tumor-to-tissue contrast ratios are presented in Figure S18 . Error bars correspond to one standard deviation.
shows that the chemical efficiency of simultaneous photoradiolabeling is comparable to many of the most efficient thermally mediated methods, which typically display $60%-80% conjugation efficiency (Holland et al., 2010b (Holland et al., , 2010a Rylova et al., 2016; Verel et al., 2003a Verel et al., , 2003b Vosjan et al., 2010) . Under the conditions employed it is likely that the kinetics of metal ion complexation is equal to, or faster than, that of the photochemical conjugation step. Complexation of 89 Zr 4+ ions by the DFO-ArN 3 chelate reduces the probability of intramolecular reactions between the nucleophilic hydroxamate groups and the photo-generated intermediates. Hence, pre-complexation increases the photochemical conjugation efficiency when compared with the free chelate (1) . Notably, the photoradiochemical method is also suitable for use in fully automated radiochemical synthesis modules. Automated photoradiochemical synthesis has the potential to change the way in which radiolabeled mAbs, immunoglobulin fragments, and other proteins are produced in the clinic.
Conclusions
Experiments demonstrated that the photoradiolabeling methods are viable for the synthesis of radiolabeled antibodies for immuno-PET. In contrast to existing (thermochemical) technologies, photoradiochemistry allows for the rapid synthesis of [ 89 Zr] ZrDFO-azepin-trastuzumab in high radiochemical yield and purity using a simultaneous, one-pot approach. Accessing radiolabeled proteins directly from the non-functionalized source eliminates the need to isolate and characterize a radiolabeling precursor (here DFO-azepin-trastuzumab). Our work illustrates the potential of applying photochemistry in radiopharmaceutical science. We continue to investigate the use of photoradiochemistry with different photoactivatable groups, chelates, and radionuclides for producing diagnostic and therapeutic radiopharmaceuticals based on proteins, peptides, small molecules, and nanoparticles.
Limitations of the Study
Although photoradiochemistry offers an exciting alternative for the synthesis of radiolabeled proteins, and we have shown that photoradiochemistry can facilitate processes that are not achievable using standard thermochemical methods, some limitations exist. Namely, the success of the photoradiochemical reaction is dependent on the experimental geometry. The light-activation process was found to be highly efficient, but experimentally, the shape and focus point of the light beam, the photon flux, and the potential absorption or scattering from the reaction vessel or chemical components of the reaction mixture mean that care must be taken to achieve reproducible results. Similar to standard thermochemical methods, we have also discovered that the photochemical conjugation efficiency depends on the nature of the photoactive group, the chelate or complex, and also other factors including the protein, solvent composition, mixing efficiency, and concentration-dependent radiochemical kinetics (Holland, 2018) . Much work is required before photoradiochemical methods can be standardized.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. [ZrDTPA] -control (green, equivalent to the no chelate control confirming no non-specific binding of 89 Zr 4+ ions to the mAb), a control reaction without mAb (yellow), crude reaction mixtures after irradiation and DTPA quenching at 365 nm (black) and 395 nm (red), and the purified product (blue).
SUPPLEMENTAL INFORMATION
(C) SEC-UHPLC chromatograms of the crude and purified product. Figure S16 , related to Figure 11 and Table 1 . Bar chart showing ex vivo biodistribution data (%ID/g) for the uptake of 
Transparent methods

General details
Unless otherwise stated, all chemicals were of reagent grade and purchased from SigmaAldrich (St. Louis, MO), Merck (Darmstadt, Germany), Tokyo Chemical Industry (Eschborn, Germany), abcr (Karlsruhe, Germany) or CheMatech (Dijon, France). Water (>18.2 MΩ·cm at 25 ºC, Puranity TU 3 UV/UF, VWR International, Leuven, Belgium) was used without further purification. Solvents for reactions were of reagent grade, and where necessary, were dried over molecular sieves. Evaporation of the solvents was performed under reduced pressure by using a rotary evaporator (Rotavapor R-300, Büchi Labortechnik AG, Flawil, Switzerland) at the specified temperature and pressure.
1 H and 13 C NMR spectra were measured in deuterated solvents on a Bruker AV-400 ( 1 H: 400 MHz, 13 C: 100.6 MHz) or a Bruker AV-500 ( 1 H: 500 MHz, 13 C: 125.8 MHz) spectrometer. Chemical shifts (d) are expressed in parts per million (ppm) relative to the resonance of the residual solvent peaks, for example, with DMSO dH = 2.50 ppm and dC = 39.5 ppm with respect to tetramethylsilane (TMS, dH and dC = 0.00 ppm). Coupling constants (J) are reported in Hz. All resonances were assigned by using a combination of 1D and 2D NMR (HSQC, COSY) spectra. Peak multiplicities are abbreviated as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet), and br (broad).
High-resolution electrospray ionisation mass spectra (HR-ESI-MS) were measured by the mass spectrometry service at the Department of Chemistry, University of Zurich.
Column chromatography was performed by using Merck silica gel 60 (63 -200 µm) with eluents indicated in the experimental section. Standard thin-layer chromatography (TLC) for synthesis employed Merck TLC plates silica gel 60 on an aluminium base with the indicated solvent system. The spots on TLC were visualised either by UV/visible light (254 nm) or by staining with KMnO4.
Semi-preparative high-performance liquid chromatography (HPLC) purifications were performed using a Rigol HPLC system (Contrec AG, Dietikon, Switzerland) equipped with a C18 reverse-phase column (VP 250/21 Nucleodur C18 HTec, 21 mm ID x 250 mm, 5μm) using a flow rate of 8 mL min -1 with a linear gradient of solvent A (distilled H2O containing 0.1% TFA) and B (MeOH): t = 0-3 min., 60% A; t = 25-30 min., 5% A; t = 33-38 min., 60% A. Electronic absorption was measured at 254 nm.
Analytical ultra-high-performance liquid chromatography (UHPLC) experiments were performed using two separate Hitachi Chromaster Ultra Rs systems fitted with either a reverse phase VP 250/4 Nucleodur C18 HTec (4 mm ID x 250 mm, 5μm) column or a reverse phase Acquity UPLC column (BEH C18, 1.7 µm, 2.1 mm ID x 50 mm). One of these systems was also connected to a radioactivity detector (FlowStar 2 LB 514, Berthold Technologies, Zug, Switzerland) equipped with a 20 µL PET cell (MX-20-6, Berthold Technologies) for analysing radiochemical reactions. Proteins were analysed by using the same UHPLC system equipped with a size-exclusion column (Enrich SEC 70 column: 24 mL volume, 10 ± 2 µm particle size, 10 mm ID x 300 mm, Bio-Rad Laboratories, Basel, Switzerland). UHPLC using the Acquity column used a flow rate of 0.6 mL min -1 with a linear gradient of solvent A (distilled H2O containing 0.1% TFA) and B (acetonitrile): t = 0-0.5 min., 30% A; t = 9.5 min., 0% A; t = 10 min., 0% A. Electronic absorption was measured at 254 nm.
Analytical high performance liquid chromatography (HPLC) experiments for photodegradation kinetics were performed using a Hitachi Chromaster system equipped with a reverse phase column (Reproshell 100 Dr. Maisch C18, 2.8 µm, 75 x 4.6 mm) using a flow rate of 1.5 mL min -1 with a linear gradient of solvent A (distilled H2O containing 0.1% HCOOH) and B (acetonitrile): t = 0 min., 95% A; t = 5.8 min., 0% A; t = 6.8 min., 0% A; t = 7.3 min., 90% A. Electronic absorption was measured at 260 nm.
Electronic absorption spectra were recorded using a Nanodrop TM One C Microvolume UV-Vis Spectrophotometer (ThermoFisher Scientific, supplied by Witec AG, Sursee, Switzerland). Protein concentration was determined in accordance with the manufacturers protocol.
Photochemistry
Photochemical conjugation experiments were performed in transparent glass vials at the indicated concentrations. Stock solutions were prepared in H2O (trastuzumab and DFO-ArN3 [1] ). Photochemical reactions were stirred gently using a magnetic stir bar. Detail procedures and reaction times are indicated in the experimental section. Irradiations used three light sources. For pre-conjugation experiments, a high-powered Rayonet reactor 1 (350 nm, 16 x 8 W Sylvania BLB-lamps, 10 cm diameter) was used. For kinetic studies and for simultaneous one-pot photoradiochemical labelling reactions, portable, high-powered, light-emitting diodes (LEDs at either 365 nm or 395 nm) were used. The LED intensity was adjusted using a UV-LED controller (Opsytec Dr. Gröbel GmbH, Ettlingen, Germany), where 100% corresponded to a power of approximately 263 mW and 355 mW for the 365 nm and 395 nm sources, respectively. LED intensity was measured using a S470C Thermal Power Sensor Head, Volume Absorber, 0.25 -10.6 µm, 0.1mW -5W, Ø15 mm. Total irradiance power of the Rayonet reactor was estimated to be approximately 92 mW (approximately 300 mW/cm 3 ). Note that calculation of exact power incident to the reaction is non-trivial because it depends on the specific geometry of the experimental set-up. The temperature of all photochemical conjugation reactions was typically 23 ± 2 o C. Emission spectra of the three light sources are shown in Figure S1 . The Rayonet reactor had an experimentally measured lmax at 368 nm with full-width at half-maximum (FWHM) value of 16.0 nm. The LED (365 nm) had a maximum emission intensity at 364.5 nm (FWHM of 9.1 nm). The LED (395 nm) had a maximum emission intensity at 389.9 nm (FWHM of 9.1 nm). 
Radioactivity and radioactive measurements
All instruments for measuring radioactivity were calibrated and maintained in accordance with previously reported routine quality control procedures. (aq.) was obtained as a solution in ~1.0 M oxalic acid from PerkinElmer (Boston, MA, manufactured by the BV Cyclotron VU, Amsterdam, The Netherlands) and was used without further purification. Radioactive reactions were monitored by using instant thin-layer chromatography (radioiTLC). Glass-fibre iTLC plates impregnated with silica-gel (iTLC-SG, Agilent Technologies) were developed in using aqueous mobile phases containing either EDTA (50 mM, pH7.1) or DTPA (50 mM, pH7.4) and were analysed on a radio-TLC detector (SCAN-RAM, LabLogic Systems Ltd, Sheffield, United Kingdom). Radiochemical conversion (RCC) was determined by integrating the data obtained by the radio-TLC plate reader and determining both the percentage of radiolabelled product (Rf = 0.0) and 'free' 89 Zr (Rf = 1.0; present in the analyses as either [ 89 Zr]Zr(EDTA) or [ 89 Zr]Zr(DTPA) . Integration and data analysis were performed by using the software Laura version 5.0.4.29 (LabLogic) . Appropriate background and decay corrections were applied as necessary. Radiochemical purities (RCPs) of labelled protein samples were determined by size-exclusion chromatography (SEC) using two different columns and techniques. The first technique used an automated size-exclusion column (Bio-Rad Laboratories, ENrich SEC 70, 10 ± 2 µm, 10 mm ID x 300 mm) connected to a UHPLC device (Hitachi ChromasterUltra Rs, VWR International, Leuven, Belgium) equipped with a UV/visible diode array detector (absorption measured at 220, 254 and/or 280 nm) as well as a radioactivity detector (FlowStar 2 LB 514, Berthold Technologies, Zug, Switzerland). Isocratic elution with phosphate buffered saline (PBS, pH7.4) was used. The second method used a manual procedure involving size-exclusion column chromatography using a PD-10 desalting column (Sephadex G-25 resin, 85-260 µm, 14.5 mm ID x 50 mm, >30 kDa, GE Healthcare). For analytical procedures, PD-10 columns were eluted with sterile saline or PBS. A total of 40 x 200 µL fractions were collected up to a final elution volume of 8 mL. Note that the loading/dead-volume of the PD-10 columns is precisely 2.50 mL which was discarded prior to aliquot collection. For quantification of radioactivity, each fraction was measured on a gamma counter (HIDEX Automatic Gamma Counter, Hidex AMG, Turku, Finland) using an energy window between 480 -558 keV for 89 Zr (511 keV emission) and a counting time of 30 s. Appropriate background and decay corrections were applied throughout. PD-10 SEC columns were also used for preparative purification and reformulation of radiolabelled products by collecting a fraction of the eluate corresponding to the high molecular weight protein (>30 kDa fraction eluted in the range between 0.0 to 1.6 mL as indicated for each experiment).
Cell culture
For cell binding assays, the human ovarian cancer cell line SK-OV-3 (HER2/neu-positive, American Type Culture Collection [ATCC-HTB-77], Manassas, VA) was used. Cells were cultured at 37 °C in a humidified 5% CO2 atmosphere in DMEM/F12 (1:1) (Dulbecco's Modified Eagle Medium, F-12 Nutrient mixture (Ham), ThermoFisher Scientific, Schlieren, Switzerland) medium containing [+] -L-glutamine (2.5 mM), supplemented with fetal bovine serum (FBS, 10% (v/v), ThermoFisher Scientific) and penicillin/streptomycin (P/S, 1% (v/v) of penicillin 10000 U/mL and streptomycin 10 mg/mL). Cells were grown by serial passage and were harvested by using trypsin (0.25%).
Cell binding assays (immunoreactivity)
Cell binding assays were performed in accordance with the following general procedure. SK-OV-3 cells were harvested using trypsinisation (0.25%) and collected by centrifugation (2000 RPM, 10 min.). The medium was removed and the cell pellet was resuspended in complete medium containing NaN3 (0.1% w/w). Subsequently, a two-fold serial dilution of the number of cells was performed. Cell stocks ranging from 5 x 10 6 cells to 15 x 10 4 cells were prepared in six microcentrifuge tubes with each tube containing a final volume of 0.5 mL cell suspension. One of the four prepared dilution series was incubated with a 6000-fold molar excess of non-radiolabelled trastuzumab (98.9 µg, 0.682 nmol) with respect to [ 89 Zr]ZrDFO-azepin-trastuzumab for 1 h prior to the addition of the radiotracer as a control for accessing non-specific binding. [ 89 Zr] ZrDFO-azepin-trastuzumab formulated in sterile PBS was prepared in accordance with the procedures described below. For cell binding assays, [ 89 Zr]ZrDFO-azepin-trastuzumab (6.8 µL, 2.22 µg of protein, 0.0153 nmol, 200 kBq) was diluted with PBS (13.5 mL). A constant amount of diluted [ 89 Zr] ZrDFO-azepin-trastuzumab was added to each Eppendorf tube containing the cell suspensions (100 µL per sample, containing ~0.0164 µg of protein, 1.1 x 10 -13 mol, ~1.5 kBq). Cells were subsequently incubated while keeping them in suspension by shaking. After 1 h at 37 °C, the Eppendorf tubes were placed on ice and the cells were pelleted by centrifugation (4 °C, 3000 RPM, 5 min.). The medium was discarded and the pellets were washed with ice cold PBS (2 x 0.5 mL, centrifugation at 4 °C, 3000 RPM, 5 min.). Important: Cells were kept on ice throughout the entire washing procedure to minimise the rate of dissociation. Subsequently, the radioactivity in each pellet was quantified with the gamma counter. Standard samples of the radiotracer (3 x 100 µL) were kept separately and served as a reference of initial radioactivity added to the cells.
The immunoreactive fraction of [
89 Zr]ZrDFO-azepin-trastuzumab was estimated by plotting standard saturation binding curves. In addition, the immunoreactive fraction was also estimated by using procedures reported by Lindmo et al. 4 Linear regression analysis of a plot of (total/bound) activity versus (1/[number of cells]) yielded the immunoreactive fraction calculated as 1/y-intercept.
Stability studies
The stability of [ 89 Zr]ZrDFO-azepin-trastuzumab with respect to change in radiochemical purity due to loss of radioactivity from the protein fraction was investigated in vitro by incubation in human serum. Aliquots of [ 89 Zr]ZrDFO-azepin-trastuzumab (250 µL, 81.5 µg, 0.54 nmol, 6.59 MBq, Am ~12.1 MBq/nmol) were added to human serum (400 µL) giving a total reaction volume of 650 µL. Solutions were incubated at 37 o C and SEC-UHPLC measurements recorded at the specified time points up to 45 h. The stability was monitored by quantifying the radioactivity associated with intact [ 89 Zr] ZrDFO-azepin-trastuzumab from integration of the decay corrected SEC-UHPLC radioactive chromatograms.
Animals and xenograft models
All experiments involving mice were conducted in accordance with an animal experimentation licence approved by the Zurich Canton Veterinary Office, Switzerland (Jason P. Holland). Experimental procedures also complied with guidelines issued in the Guide for the Care and Use of Laboratory Animals. 6 Tumours developed after a period of between 3 -6 weeks. Tumour volume (V / mm 3 ) was estimated by external Vernier caliper measurements of the longest axis, a / mm, and the axis perpendicular to the longest axis, b / mm. The tumours were assumed to be spheroidal and the volume was calculated in accordance with Equation S1.
(Equation S1)
Small-animal PET imaging
All mice injected with cancer cells developed tumours and the average volume of the SK-OV-3 tumours was 196 ± 74 mm 3 (n = 12 mice). Mice were randomised before the study. The tail of each mouse was warmed gently using a warm water bath immediately before administering [ 89 Zr]ZrDFO-azepin-trastuzumab (normal group n = 6 mice / group: 1.02 -1.09 MBq, [27.5 -29.6 µCi], 13.75 µg of protein, in 250 µL sterile PBS) via intravenous (i.v.) tail-vein injection (t = 0 h). Competitive inhibition studies (blocking group: n = 6 mice / group, µCi], 1.4 mg of total protein, in 250 µL sterile PBS) were also performed to investigate the specificity and biological activity of the radiotracer in vivo. Note that one mouse in the normal group was excluded from the experiment and data analysis due to an aberrant pharmacokinetic profile in which the radiolabelled antibody was rapidly extracted from circulation and accumulated almost entirely in the liver and spleen within ~8 h post-administration. Further details on this phenomenon will be reported elsewhere. Full details on radioactive dose preparation are given below. Briefly, to prepare the blocking dose, an aliquot of non-radiolabelled trastuzumab (stock solution containing 57.7 mg/mL of protein in sterile saline) was added to the [ 89 Zr]ZrDFO-azepin-trastuzumab formulation (~98-times more protein compared to the normal group).
PET imaging experiments were conducted on a Genesis G4 PET/X-ray scanner (Sofie Biosciences, Culver City, CA). 7 Approximately 5 minutes prior to recording each PET image, mice were anesthetised by inhalation of between 2 -4% isoflurane (Attane TM , Piramal Enterprises Ltd, India, supplied by Provet AG, Lyssach, Switzerland)/oxygen gas mixture and placed on the scanner bed in the prone position. PET images were recorded at various time-points between 2 h and 94 h post-administration of the radiotracer. During image acquisition, the respiration rate of the animal was monitored via live video feed and anaesthesia was maintained by an experience animal experimenter by controlling the isoflurane dose between 1.5 -2.0%. List-mode data were acquired for 10 min. using a γ-ray energy window of 150-650 keV, and a coincidence timing window of 20 ns. Images were reconstructed by iterative ordered subset maximum expectation (OSEM; 60 iterations) protocols. The reported reconstructed spatial resolution is 2.4 µL at the centre of the field-of-view (FOV). Image data were normalised to correct for non-uniformity of response of the PET, attenuation, random events, dead-time count losses, positron branching ratio, and physical decay to the time of injection, but no scatter or partial-volume averaging correction was applied. An empirically determined system calibration factor (in units of [Bq/voxel] were drawn manually to determine the maximum and mean accumulation of radioactivity (in units of %ID/cm 3 and decay corrected to the time of injection) in various tissues. Where appropriate, data were also converted into mean standardised uptake values (SUVmean).
Biodistribution studies
Biodistribution studies were conducted after the final imaging time point to evaluate the radiotracer uptake in tumourbearing mice. Animals (n = 6 mice / group) were anaesthetised individually by isoflurane and euthanised by isoflurane asphyxiation followed by terminal exsanguination. Note: one mouse was excluded from the analysis of the data from the normal group (vide supra). A total of 15 tissues (including the tumour) were removed, rinsed in water, dried in air for approx. 2 min., weighed and counted on a calibrated gamma counter for accumulation of activity. The mass of radiotracer formulation injected into each animal was measured and used to determine the total number of counts per minute (cpm) injected into each mouse by comparison to a standard syringe of known activity and mass. Count data were background-and decay-corrected, and the tissue uptake for each sample (determined in units of percentage injected dose per gram [%ID/g]) was calculated by normalisation to the total amount of activity injected for each individual animal. For comparison purposes, data are also presented in terms of SUV.
Effective half-life, t1/2(eff)
The effective half-life t1/2(eff) of [ 89 Zr] ZrDFO-azepin-trastuzumab was measured in the same athymic nude mice used for small-animal PET imaging and end time point biodistribution. Total internal radioactivity was measured as a function of time by using a dose calibrator.
Computational details
All calculations were conducted using density functional theory (DFT) as implemented in the Gaussian16 Revision A.03 suite of ab initio quantum chemistry programs. Normal self-consistent field (SCF) and geometry convergence criteria were employed throughout. All structures were optimised in the gas phase and in solution phase using a polarisable continuum model (PCM). With the exception of calculations on the arylnitrene (ArN) intermediate which were calculated using C2v symmetry, all other structures were optimised without using symmetry constraints. Solvated phase calculations were implemented using the SCRF keyword with default parameters and selecting water as the solvent (dielectric constant, e = 78.3553). Harmonic frequency analysis based on analytical second derivative was used to characterise optimised structures as local minima or first order saddle points (transition states) on the potential energy surface. Calculations were performed using the unrestricted uB3LYP exchange-correlation functionals and the triple-ζ 6-311++G(d,p) A2 state. Geometry optimisation of ArN in the triplet state was accomplished by specifying the triple state in the root section. Optimisation to the lowest energy open-shell singlet 1 A2 state required control over the molecular orbital population using the Guess=(always,alter) keyword. The initial orbital population guess placed both the alpha and beta electrons in the highest occupied molecular orbitals (HOMOs) which had B2 symmetry and corresponding to the in-plane py orbital on the N atom. In both the alpha and beta orbital manifolds the lowest unoccupied molecular orbital (LUMO) had B1 symmetry and corresponded to the to the out-of-plane px orbital on the N atom. Convergence to the 1 A2 state was achieved by switching the orbital occupancy from the 24(B2) orbital to the 25(B1) orbital in the beta manifold. Note that spin contamination was observed in the optimised 1 A2 state calculations with the spin expectation value of <S2> = 1.000 indicating a 50:50 mixture with a triplet contamination. Therefore, energies of the 1 A2 state were estimated using the sum method reported by Ziegler et al. 3 The structure of the alternative higher energy closed-shell 1 A1 singlet state with a (px) 2 electronic configuration was also optimised using a similar control of the orbital populations.
Time-dependent density functional theory (TD-DFT) calculations were performed on the model compound arylazide (PhN3). Transition energies and oscillator strengths for electronic excitation to the first 16 excited states (including both singlet and triplet states) were calculated by using the unrestricted uB3LYP/6-311++G(d,p) methodology incorporating the default PCM in water. No symmetry constraints were used in TD-DFT calculations. The simulated TD-DFT electronic absorption spectrum in Figure 4 (main article) was calculated by using a Lorentzian line broadening function with a full-width at half maximum (FWHM) value set at 20 nm (implemented in Chemcraft). Absolute calculated transition energies were shifted linearly by D = +12 nm to optimise the overlay with the experimental spectrum but scaling factors were not used. 
Statistical analysis
Where appropriate, data were analysed by the unpaired, two-tailed Student's t-test. Differences at the 95% confidence level (P-value <0.05) were considered to be statistically significant.
Synthesis and chemical characterisation
Chemical syntheses were performed in accordance with Scheme 2 (main article). All reactions involving photosensitive compounds were performed in the dark. Herceptin TM was generously provided by Genentech (South San Francisco, CA) and was initially reconstituted in water. The IgG1 antibody component (trastuzumab) was purified from Herceptin TM by spin column centrifugation (4000 RPM, 3 x 15 min., 1 x 20 min.) by using a membrane filter (Amicon Ultra-4 mL centrifugal filter, Millipore, 10 kDa MWCO). Briefly, aliquots of Herceptin TM (60 mg) were washed with H2O (4 x 4 mL) at room temperature and concentrated before use. After concentration, protein samples were removed from the centrifugation filter by rinsing with water (500 µL) and the protein concentration was determined using a Nanodrop TM One C Microvolume UV-Vis Spectrophotometer. Typically, 25 -30 mg of protein was obtained and samples were aliquoted into Eppendorf tubes and stored at -20 ⁰C for future use.
Synthesis of desferrioxamine-p-arylazide, DFO-ArN3 (1) A solution of 4-azidobenzoic acid (206 mg, 1.26 mmol), HATU (506 mg, 1.33 mmol) and N,N-diisopropylethylamine (DIPEA, 130 µL) in dry DMF (8 mL) was stirred at room temperature for 40 min. Then desferrioxamine B mesylate (DFO, 407 mg, 0.725 mmol) was added to the mixture along with additional DIPEA (95 µL) and N-methylmorpholine (250 µL). After stirring at room temperature for 80 h, the mixture was transferred to a single-necked round bottom flask (100 mL) and the solvent was evaporated under reduced pressure (25 mbar). The orange-beige residue was washed by sonication with cold acetone (6 x 7 mL, -20 °C) and ice-cold H2O (4 x 7 mL). Note that between each washing step, the solid residue was collected by centrifugation and cooled. Washing with acetone the orange colour and subsequent lyophilisation gave the crude product DFO-ArN3 (1, 40% yield, 228 mg, 0.291 mmol, estimated 68% purity measured by 1 H NMR) as a white amorphous powder. A portion of the crude product was purified by semipreparative HPLC and after lyophilisation, purified compound 1 was obtained as a white amorphous powder. (Yield 4%, estimated purity >95% by UHPLC and by 1 H NMR). 4+ ions dissolved in 0.1 M HCl(aq.)) was added dropwise. The reaction was monitored by RP-UHPLC and after stirring at room temperature for 2 h, complete conversion was observed. Presence of desired product Zr-1 + was confirmed by a single peak in analytical HPLC that gave the expected mass of molecular ion as the base peak in high-resolution electrospray ionisation mass spectrometry (see Figure 1 
Photochemical reaction kinetics
DFO-ArN3 (1, 0.31 mg, 0.44 µmol) was dissolved in H2O (266 µL) and NaOH(aq.) (21 µL of a 0.1 M stock solution) in a transparent reaction vial equipped with a magnetic stir bar. Immediately before starting the photochemical conjugation reactions, the pH of the DFO-ArN3 solution was reduced to ~8 -9 by the addition of HCl(aq.) (12.6 µL of a 0.1 M stock solution). The sample was irradiated directly from above with a sheet of white paper placed between the vial and the stirring plate. The reactions (performed in duplicate) were irradiated at the specified LED intensity and aliquots (30 µL) were removed at the given time points and analysed by electronic absorption UHPLC. Photochemical degradation kinetic data are presented in Figure 2 (main article) and Table S2 . Table S2 , related to Figure 2 . Experimental data on the change in the relative concentration of [ZrDFO-ArN3] + (Zr-1 + ) during irradiation at 365 nm with the specified LED intensity. 89 Zr-1 + (Rf = 0.0) was observed in <10 min. Aliquots of the crude reaction mixture were analysed be radioactive HPLC (Figure 1 , main text). A single peak was observed in the radioactive trace. The identity of the radiolabelled compound 89 Zr-1 + was confirmed by co-injection with an authenticated sample of nat Zr-1 + . tR (RP-HPLC) = 9.48 min. (detection at l = 220, 254 and 280 nm, Figure 1 , main text). RP-HPLC method: A flow rate of 0.7 mL min -1 with a linear gradient of A (distilled H2O containing 0.1% TFA) and B (acetonitrile): t = 0 min, 90% A; t = 20 min, 10% A.
Photochemical conjugation
General procedure for photochemical conjugation: A stock solution of photoactive ligand was prepared by dissolving DFO-ArN3 (1, 0.85 mg, 1.21 µmol) in water (50 µL) and NaOH(aq.) (40 µL of a 0.1 M stock solution). Immediately before starting the photochemical conjugation reactions, the pH of the DFO-ArN3 solution was reduced to ~9 by the addition of HCl(aq.) (2 x 10 µL of a 0.1 M stock solution). Note: DFO-ArN3 (1) is sparingly soluble at high pH but starts to precipitate slowly when the pH decreases below ~9. For this reason, photochemical reactions should be initiated immediately after adding the HCl and the protein. After adjusting the pH, aliquots of the DFO-ArN3 stock solution were added to clear 2 mL glass vials equipped with small magnetic stirring bars and containing an aqueous solution of trastuzumab (120 µL, 2.76 mg, 1.84 x 10 -8 mol, stock protein concentration = 23.0 mg/mL) and a variable amount of water (constant total reaction volume = 200 µL). The chelate-to-mAb ratio was varied used 5.3-fold (9 µL), 10.7-fold (18 µL) or 26.4-fold (45 µL) excess of DFO-ArN3 stock solution. The final pH of the solutions was 8-8.5. The reaction mixture was then irradiated for 25 min. using the Rayonet reactor. The irradiated crude mixture was then purified by a three-step procedure. First, the mixture was taken in a 30 kDa MWCO membrane centrifugal filter (Amicon Ultra-4 mL centrifugal filter, Millipore,), concentrated and washed with PBS (2 x 4 mL) using centrifugation (4000 RPM, ~15 min). Then the mixture was purified using a preparative PD-10-SEC column (eluted with PBS, collecting the 0.0 -1.6 mL fraction immediately after discarding the 2.5 mL column dead volume). In the last step, the initial chelate-to-mAb ratios are given in Figure S11A and S11B. After allowing sufficient time for saturation of the accessible chelates (180 min.), the final RCC was used to estimate the number of accessible chelates per antibody using the measured (decay corrected) molar activity of [ 89 Zr] [Zr(C2O4)4] 4-and the known number of moles of antibody added to each reaction. Note that it was assumed that Zr 4+ ions form a 1:1 stoichiometric complex with DFO ( Figure  S11C ). The measured accessible chelate-to-mAb ratios were 0.27, 0.55 and 0.85 for DFO-azepin-trastuzumab samples prepared at initial chelate-to-mAb ratios of 5.3, 10.7 and 26.4, respectively . Linear regression analysis indicated that the quantum yield for photochemical coupling of compound 1 with trastuzumab was ~0.035. The relatively low efficiency is likely due to intramolecular reactions between the activated nitrene, benzazirine or ketenimines intermediates are nucleophilic groups (like hydroxamate anions) in the structure of DFO. See the main text for further discussions about the quantum yield and photochemical conjugation efficiency using 89 Zr-1 + .
Figure S11, related to Figure 7 . Radio-ITLC data showing the change in radiochemical conversion versus time for the radiosynthesis of [ 89 Zr] ZrDFO-azepin-trastuzumab using pre-photochemically conjugated DFO-azepintrastuzumab samples prepared with an initial chelate-to-mAb ratio of (A) 5.3-fold, and (B) 10.7-fold. (C) Plot of the experimentally determined accessible chelate-to-mAb ratio versus the initial chelate-to-mAb ratio used in the photochemical conjugation step. Table 1 . Bar chart showing a comparison between the measured tumour-totissue contrast ratios calculated from the ex vivo biodistribution data (in units of %ID/g) for the uptake of [ 89 Zr] ZrDFOazepin-trastuzumab in mice bearing SK-OV-3 tumours, and previously reported biodistribution data on the uptake of [ 89 Zr]ZrDFO-Nsucc-trastuzumab in mice bearing BT-474 tumours.
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